Bladder seen through a cystoscope under blue light - Courtesy of Professor Dirk Zaak; Traunstein, Germany

Learn about our Technology Making bladder cancer visible


Latest News See more news
  • 16.10.2020
    New data analysis on Blue Light Cystoscopy efficiency presented at the virtual BLADDR 2020 congress

    PRESS RELEASE – Oslo, Norway, 16 October, 2020: Photocure ASA (OSE:PHO) today announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC registry, an ongoing prospective multicenter study. It demonstrates that flexible Blue Light Cystoscopy helped resolve a substantial amount of cases by complete removal on-site or direct referral to intravesical treatment, providing increased efficacy to manage non-muscle-invasive bladder cancer (NMIBC) in the office setting.

  • 05.10.2020
    Photocure announces new Cevira patent in Europe

    Oslo, Norway, 5 October 2020: Photocure ASA (OSE:PHO) today announces that the European Patent Office (EPO) has granted patent EP 2983780 covering the commercial Cevira® device in Europe until 2034.

  • 01.10.2020
    Photocure launches European Hexvix operations

    Oslo, Norway, 1 October 2020: Photocure ASA (OSE:PHO) today announces the commencement of the sales, marketing and distribution of Hexvix® in the European markets formerly operated by Ipsen Pharma SAS (Ipsen). The successful transition and launch of European Hexvix operations creates a robust platform for accelerated growth and expansion for Photocure.

Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients